Citable filing context
ABBV's research view summarizes recent SEC filing context, starting with acquisition from Sep 3, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 3, 2026 | acquisition | AbbVie completed its acquisition of Apogee Therapeutics, Inc. for approximately $10.9 billion in cash. |
| Aug 18, 2026 | debt_offering | AbbVie completed a $10 billion senior notes offering to fund its acquisition of Apogee Therapeutics, Inc. |
| Aug 5, 2026 | debt_offering | AbbVie issued $9.93 billion in senior notes to fund the acquisition of Apogee Therapeutics, Inc. |
| Sep 3, 2026 | Guidance: adjusted_diluted_eps | 3.84 to 3.88 |
| Sep 3, 2026 | Guidance: adjusted_diluted_eps | 13.87 to 14.07 |
| Jul 31, 2026 | Guidance: adjusted_diluted_eps | 13.87 to 14.07 |
| Aug 3, 2026 | mda_quarterly | AbbVie reported strong financial performance for the first half of 2026, with worldwide net revenues of $32.0 billion, an 11% increase on a reported basis. Growth was primarily driven by the immunology portfolio, specifically Skyrizi and Rinvoq, which saw revenue increases of 27% and 24%, respectively. Conversely, Humira revenues declined 37% due to biosimilar competition. Neuroscience remains a key growth pillar, with Vraylar, Ubrelvy, and Qulipta showing double-digit revenue gains. The company maintains a robust pipeline with approximately 90 programs, including 60 in mid-to-late-stage development. Strategic capital allocation remains focused on R&D and business development, highlighted by a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, expected to close in the third quarter of 2026. To support this, AbbVie secured a $10.0 billion term loan facility. Operational risks include ongoing litigation, such as the Allergan breast implant product liability cases, for which a resolution was reached in June 2026. Additionally, the company faces regulatory pressure from the Inflation Reduction Act, with Botox selected for Medicare price negotiations beginning in 2028. AbbVie’s liquidity remains strong, supported by $6.6 billion in cash and equivalents and investment-grade credit ratings. |
| May 8, 2026 | mda_quarterly | AbbVie executed significant share repurchases during the first quarter of 2026, acquiring a total of 4,623,720 shares. The bulk of this activity occurred in March, with 4,621,835 shares purchased at an average price of $230.40, largely under a publicly announced program. Minor repurchases also took place in January (976 shares at $222.49) and February (909 shares at $223.56), with some shares allocated to the employee stock purchase plan. Following these transactions, approximately $1.83 billion remained authorized for future share repurchases. For the quarter ended March 31, 2026, no directors or officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements. The filing further details the company's employee equity compensation framework, including Performance-Vested Restricted Stock Units, Performance Share Awards, and Non-Qualified Stock Options, outlining their vesting conditions, forfeiture clauses, and tax withholding mechanisms, which are integral to AbbVie's long-term incentive structure. |
Source: SEC EDGAR filing text and events; period Sep 3, 2026; filed Sep 3, 2026.
ABBV company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.